ARB candesartan and CCB amlodipine in hypertensive patients: The CASE-J trial

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 9, 2008, Pages 1195-1201

  Ogihara, Toshio ^a   Fujimoto, Akira ^b   Nakao, Kazuwa ^b   Saruta, Takao ^c  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c School of Medicine Graduate School of Medicine   (Japan)

Author keywords

Angiotensin II receptor blocker; Antihypertensive therapy; Calcium channel blocker; Cardiovascular morbidity and mortability; Clinical trial; Hypertension

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CREATININE;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; EDEMA; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERTENSION; INCIDENCE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMONIA; POTASSIUM BLOOD LEVEL; PROTEINURIA; RISK REDUCTION; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TETRAZOLES;

EID: 55349147316     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.9.1195     Document Type: Article

References (31)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367, 1747-1757 (2006).
3. Goodfriend TL, Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. N. Engl. J. Med. 334, 1649-1654 (1996).
4. Messeli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition: a new therapeutic principle. Arch. Intern. Med. 156, 1957-1965 (1996).
5. Staessen JA, Fagard T, Thijs L et al.; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350, 757-764 (1997).
6. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001).
7. Brenner BM, Cooper ME, de Zeeuw D et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
8. Demers C, McMurray JJ, Swedberg K et al.; CHARM Investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 294, 1794-1798 (2005).
9. Dahlof B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002).
10. Davis BR, Furberg CD, Wright JT et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The antihypertensive and lipid lowering treatment to prevent heart attack Trial (ALLHAT). JAMA 283, 1967-1975 (2000).
11. Brown M, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 356, 366-372 (2000).
12. WHO; International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 21, 1983-1989 (2003).
13. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the joint National Commitee on prevention, detection, evaluation, and treatment of high blood pressure (The JNC 7 Report). JAMA 289, 2560-2572 (2003).
14. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28, 1462-1536 (2007).
15. Fukui T, Rahman M, Hayashi K et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens. Res. 26, 979-990 (2003).
16. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan. Antihypertensive Survival Evaluation in Japan trial. Hypertension 51, 393-398 (2008).
17. Japanese Society of Hypertension Guidelines Subcommittee for the management of hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens. Res. 24, 613-634 (2001).
18. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 57, 450-458 (1986).
19. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 115, 41-46 (2003).
20. Devereux RB, Dahlöf B, Gerdts E et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial. Circulation 110, 1456-1462 (2004).
21. Mitsunami K, Inoue S, Maeda K et al. Three-month effects of candesartan cilexetil, an angiotensin II Type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc. Drugs Ther. 12, 469-474 (1998).
22. Cuspidi C, Muiesan ML, Valagussa L et al.; CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. hypertens. 20, 2293-2300 (2002).
23. Kjeldsen SE, Julius S, Mancia G et al. VALUE Trial Investigators. Effects of valsartan compared with amlodipine on preventing Type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J. hypertens. 24, 1405-1412 (2006).
24. Lindholm LH, Ibsen H, Borch-Johnsen K et al. LIFE study group. Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J. Hypertens. 20, 1879-1886 (2002).
25. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369, 201-207 (2007).
26. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97, 48-54 (1998).
27. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am. J. Hypertens. 15, 1021-1028 (2002).
28. Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292, 2350-2356 (2004).
29. Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43, 963-969 (2004).
30. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the valsartan antihypertensive long-term use evaluation (VALUE) trial population. Hypertension 50, 467-473 (2007).
31. Held C, Gerstein HC, Yusuf S et al.; ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk Circulation 115, 1371-1375 (2007).